

ALTEON INC /DE  
Form 8-K  
June 10, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 9, 2005**

---

**ALTEON INC.**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction  
of incorporation)**

**001-16043**  
**(Commission File Number)**

**13-3304550**  
**(IRS Employer  
Identification No.)**

**6 Campus Drive**  
**Parsippany, New Jersey 07054**  
**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (201) 934-5000**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

ITEM 8.01 OTHER EVENTS.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

SIGNATURES

EXHIBIT INDEX

PRESS RELEASE DATED JUNE 9, 2005

---

**Table of Contents**

**ITEM 8.01 OTHER EVENTS.**

On June 9, 2005, Alteon Inc. (the Registrant ) issued a press release announcing that it was discontinuing its systolic blood pressure study of alagebrium following an interim efficacy review. The Registrant also announced that the U.S. Food and Drug Administration has placed a clinical hold on further study enrollment in the Registrant's Phase 2a study of alagebrium in erectile dysfunction.

The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibit.

99.1 Press Release dated June 9, 2005.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALTEON INC.**

Dated: June 10, 2005

/s/ Kenneth I. Moch  
Kenneth I. Moch  
President and Chief Executive Officer

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press Release dated June 9, 2005.